Dominican company based in Santo Domingo · We only ship within the Dominican Republic · No international shippingDominican Republic only · No international shipping
ES Home Catalog Education COAs Calculator Founder
LL-37
Renova Verification
  • ✓≥99% purity by HPLC + mass spectrometry
  • ✓Independent Janoshik 3rd-party analysis
  • ✓−20°C lyophilized · 2–8°C reconstituted
🧪 View COA →
Home › Products › Immune › LL-37
← Back to catalog ImmuneComing Soon

LL-37 (5 mg)

AntimicrobialCathelicidinBiofilms
$150 USD5 mg/vial
🧪 Bacteriostatic water — needed to reconstitute the lyophilized vial
💰 Buy by volume
3+ of one
Save 15%
5+ of one
Save 25%
★ Wholesale
10+ of one
Save 40%
🔀 Mix & Match · across different products: 3+ items 10% · 5+ 15% · 7+ 20%
The best discount per product is applied automatically at checkout (they don't stack). Excludes bacteriostatic water; Retatrutide and Tirzepatide only get same-product volume. Can't be combined with promo codes.
🧪 COA❄️ Cold chain🛡️ Replacement guarantee🔒 Secure payment📦 Nationwide shipping🇺🇸 cGMP · ISO 9001 guidelines · COA

Only human cathelicidin peptide — broad-spectrum antimicrobial against bacteria, fungi, viruses, and resistant biofilms.

  • Mechanism: The only human cathelicidin; disrupts microbial membranes and modulates immunity.
  • Evidence: Endogenous peptide; mostly preclinical research.
  • In context: Can be pro-inflammatory; limited human data.

Not in stock yet. Message us on WhatsApp and we'll let you know as soon as it arrives.

Rango de investigación · SC
50–200 mcg per application · once daily
🔴 Research convention · SC convention; no clinical SC data

Ranges cited in research literature. Not a usage recommendation. For research use only.

📋 Technical datasheet · Compound specifications
CompoundLL-37
Origin🇺🇸 From US-based suppliers that follow strict cGMP & ISO 9001 guidelines
FormLyophilized in sterile vial (or pre-mixed solution depending on SKU)
Molecular formulaC205H340N60O53
Molecular weight4493.3 g/mol
Purity≥99% by HPLC + mass spectrometry (Janoshik Analytical)
StorageLyophilized: −20°C to −80°C, dry, dark · Reconstituted: 2–8°C · stability varies by peptide (see the reconstitution guide and the product COA)
Recommended solventBacteriostatic water (0.9% benzyl alcohol) or 0.9% saline
Cold chain2–8°C in transit · controlled thermal packaging
UseResearch Use Only (RUO). Not intended for human or veterinary use.

Typical values for this compound category. For product-specific data, see the corresponding COA at /en/coa/.

This product is exclusively for research purposes. Not intended for human use, consumption, or therapeutic applications. For laboratory use only under qualified supervision.

LL-37: research profile

LL-37 is the only peptide of the cathelicidin family that humans produce. It is generated by proteolytic cleavage of the precursor protein hCAP18, stored in neutrophil granules and also produced by keratinocytes and epithelial cells; the name comes from its two initial leucines and its 37 amino acids. Its expression is regulated by vitamin D, which induces the CAMP gene, one of the best-documented links between that vitamin and innate immunity.

In solution it adopts an amphipathic α-helix with a cationic face and a hydrophobic one, which lets it insert into bacterial membranes and destabilize them: it is active against Gram-positive and Gram-negative bacteria, fungi, enveloped viruses and biofilms. But its role goes beyond the antimicrobial: it acts as an immune signal through receptors such as FPR2 and P2X7, is chemotactic for neutrophils and monocytes, promotes angiogenesis and wound re-epithelialization and, in excess, is pro-inflammatory: in psoriasis it forms complexes with self-DNA that activate TLR9, and in rosacea its abnormal processing contributes to inflammation.

That dual character is the key to reading its literature. Clinical development has focused on the topical route: a Phase 2b trial with LL-37 (ropocamptide) in chronic venous leg ulcers showed healing signals in moderately sized ulcers, without reaching approval. There are no clinical data on systemic administration, and owing to its cationic nature it is cytotoxic at high concentrations. Renova distributes it for research only.

LL-37 technical data

ClassHuman cathelicidin (host-defense antimicrobial peptide)
SequenceLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (37 aa, amphipathic α-helix)
CAS154947-66-7
Precursor / genehCAP18 · CAMP gene (vitamin D-inducible)
ActivityBroad-spectrum antimicrobial (membranes, biofilms); signaling via FPR2, P2X7; chemotaxis; angiogenesis
Dual facePro-inflammatory in excess (psoriasis: LL-37–DNA–TLR9 complexes; rosacea)
Clinical developmentTopical: Phase 2b in venous ulcers (ropocamptide); no systemic data
HandlingCationic: adsorbs to glass/plastic surfaces; cytotoxic at high concentrations; avoid freeze–thaw cycles

Questions about LL-37

Why is LL-37 the only one of its family in humans?

Because the human genome contains a single cathelicidin gene, CAMP, which encodes the hCAP18 protein; when cleaved it releases the 37-amino-acid peptide. Other species have several cathelicidins; humans have only this one, which concentrates antimicrobial and immune functions in it.

What does vitamin D have to do with LL-37?

The active form of vitamin D induces transcription of the CAMP gene in macrophages, keratinocytes and epithelial cells, increasing LL-37 production. It is one of the best-documented mechanisms by which vitamin D takes part in innate defense against infection.

Can LL-37 be harmful?

In excess or when abnormally processed, yes: in psoriasis it forms complexes with self-DNA that activate TLR9 and fuel inflammation, and in rosacea its abnormal processing contributes to symptoms. At high concentrations it is also cytotoxic to human cells. That is why the literature describes it as a double-edged molecule.

Are there clinical trials of LL-37?

Yes, by the topical route: a Phase 2b trial with LL-37 (ropocamptide) in chronic venous leg ulcers showed healing signals in moderately sized ulcers, without reaching approval. There are no trials of systemic administration; the research market's subcutaneous route lacks clinical data.

Related reading: LL-37: The Human Antimicrobial Peptide · Thymosin Alpha-1: The Thymic Immunomodulating Peptide

Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.

Questions? Write us

Your Order

Your cart is empty